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Methyl-beta-cyclodextrinAnalysis of membrane lipids of Histoplasma capsulatum showed that ~40% of fungal ergosterol is present in
membrane microdomain fractions resistant to treatment with non-ionic detergent at 4 °C. Speciﬁc proteins
were also enriched in these fractions, particularly Pma1p a yeast microdomain protein marker (a plasma
membrane proton ATPase), a 30 kDa laminin-binding protein, and a 50 kDa protein recognized by anti-α5-
integrin antibody. To better understand the role of ergosterol-dependent microdomains in fungal biology
and pathogenicity, H. capsulatum yeast forms were treated with a sterol chelator, methyl-beta-cyclodextrin
(mβCD). Removal of ergosterol by mβCD incubation led to disorganization of ergosterol-enriched microdo-
mains containing Pma1p and the 30 kDa protein, resulting in displacement of these proteins from
detergent-insoluble to -soluble fractions in sucrose density gradient ultracentrifugation. mβCD treatment
did not displace/remove the 50 kDa α5-integrin-like protein nor had effect on the organization of glyco-
sphingolipids present in the detergent-resistant fractions. Ergosterol-enriched membrane microdomains
were also shown to be important for infectivity of alveolar macrophages; after treatment of yeasts with
mβCD, macrophage infectivity was reduced by 45%. These ﬁndings suggest the existence of two populations
of detergent-resistant membrane microdomains in H. capsulatum yeast forms: (i) ergosterol-independent
microdomains rich in integrin-like proteins and glycosphingolipids, possibly involved in signal transduction;
(ii) ergosterol-enriched microdomains containing Pma1p and the 30 kDa laminin-binding protein; ergosterol
and/or the 30 kDa protein may be involved in macrophage infectivity.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
Fungal infections have received considerable research attention in
the past two decades due to the increasing numbers of immunocom-
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sevier OA license.from low morbidity to severe systemic involvement, depending on
the etiologic agent and host immune response [1].
Membrane components (proteins, lipids, glycoconjugates) of fun-
gal cells differ from those of mammalian cells. Thus, to better under-
stand fungal infectious processes, and aiming to ﬁnd new targets for
antifungal therapy, we studied Histoplasma capsulatum membrane
microdomains and their role in host–pathogen interactions. In mam-
malians it is well known that several membrane proteins such as Lyn,
Caveolin 1 or ﬂotillin are preferentially distributed in microdomains
and may be involved in a number of biological processes as cell sig-
naling, pathogens binding and infectivity [2,3]. In this context, we
also studied the Pma1p (a plasma membrane proton ATPase), a well
known yeast microdomain marker, as well as other proteins present
in H. capsulatum yeast membrane microdomains. Classical histoplas-
mosis is caused by inhaling fragments of aerosolized hyphae and/or
conidia of this species, which are subsequently phagocytized by
host alveolar macrophages, followed by mycelium to yeast transfor-
mation. In contrast to the usual role of macrophages to eliminate
harmful microorganisms, alveolar macrophages present a favorable
environment for replication and dissemination of H. capsulatum
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control lysosomal pH [4,5].
1.1. Lipid components of H. capsulatum and other fungi
Sphingolipids are ubiquitous plasma membrane components of eu-
karyotic organisms, including fungi. These molecules are essential for
cell survival [6], and are involved in the processes of cell adhesion, prolif-
eration, differentiation, and apoptosis [7–9]. Studies from our laboratory
and others have shown that fungal membranes contain glycosphingoli-
pids (GSLs) of two types: (a) neutral monohexosylceramide (MHC), and
(b) glycoinositol phosphorylceramide (GIPC), an acidic GSL [10–12]. In
H. capsulatum, MHC is represented by glucosylceramide [13,14], while
GIPC can be represented by various GSLs, termed compound V
(Manpα1-3Manpα1-2/6Ins), VI (Galfα1-6(Manpα1-3)Manpα1-2/6Ins),
and VIII (Galpβ1-4(Manpα1-3)Manpα1-2/6Ins) [15,16]. GIPCs are not
synthesized in mammalian cells, but their expression is essential for fun-
gal viability. Therefore, GIPCs are a class of glycolipids thatmay be consid-
eredmolecules with diagnostic value for different mycosis and/or targets
for antifungal therapy [17–19].
Ergosterol, another characteristic lipid component in fungal plas-
ma membranes, similar to vertebrate cholesterol, modulates several
biological processes and also is organized in membrane microdo-
mains. The absence of ergosterol in mammals and inhibition of fungal
proliferation by ergosterol biosynthesis inhibitors point out the er-
gosterol as a target to antifungal therapy [20].
1.2. Yeast–macrophage interaction
McMahon et al. [21] reported that a 50 kDa protein present in the
H. capsulatum cell wall is able to bind to laminin, a component of the
extracellular matrix (ECM) of host lung. Adhesion of this protein to
laminin is presumably a key step in fungal pathogenesis. Adhesion
of H. capsulatum yeast to ECM promotes its phagocytosis through sur-
face receptors of alveolar macrophages, and this event inhibits pro-
duction of pro-inﬂammatory cytokines, thereby facilitating H.
capsulatum infection [22,23].
We examined the membrane microdomains of H. capsulatum, and
observed enhanced levels of speciﬁc lipid and protein components in
fractions corresponding to “detergent-resistant membrane” (DRM).
These microdomains in H. capsulatum appear to be involved in
yeast–macrophage interaction.
2. Materials and methods
2.1. Fungal growth condition
H. capsulatum, strain 496, was provided by Dra. Olga F. Gompetz,
Universidade Federal de São Paulo, São Paulo, Brazil. Yeast forms
were grown 5–7 days in BHI (brain heart infusion) medium [13], at
37 °C, with rotary shaking (100 rpm).
2.2. Isolation of detergent-resistant membrane microdomains (DRMs) by
sucrose density gradient ultracentrifugation
Yeast forms of H. capsulatum (2.5 g) were washed in ice-cold
0.01 M phosphate-buffered saline (PBS), pH 7.2. In order to disrupt
cell walls, yeast were suspended in TNE buffer (50 mM Tris–HCl,
150 mM NaCl, 5 mM EDTA, pH 7.4) containing 10 μM of leupeptin
and 2 mM of phenylmethanesulfonyl ﬂuoride and stirred with glass
beads (212–300 μm, Sigma-Aldrich, MO, USA) for 7 min at 4 °C. The
suspension was centrifuged at 800×g for 5 min at 4 °C. The superna-
tant was collected, volume adjusted to 1% Brij 98 (Sigma) in TNE buff-
er, and kept for 30 min on ice. The lysate extract was adjusted to 45%
sucrose, and then overlaid with a discontinuous sucrose density gra-
dient consisting of 30% sucrose (5.5 mL) and 5% sucrose (4 mL) inan ultracentrifuge tube. Discontinuous sucrose gradient was achieved
after centrifugation in a Sorvall AH-629 swing bucket rotor at
135,000×g for 20 h at 4 °C, and 12 fractions of 1 mL each were collect-
ed and numbered from top to bottom [24–26]. Alternatively, mam-
malian cells (NS-1) were incubated for 30 min with 1% Brij 98 at
4 °C or 37 °C, and the lysate was subjected to ultracentrifugation on
sucrose gradient in a smaller scale, to obtain 7 fractions of 1 mL
each. Aliquots of 300 μL were subjected to protein analysis by SDS-
PAGE and Western blotting, and aliquots of 700 μL were subjected
to partition with 1-butanol saturated water for lipid analysis by
high performance thin layer chromatography (HPTLC).
2.3. Treatment of H. capsulatum yeast forms with
methyl-beta-cyclodextrin (mβCD)
Yeast forms of H. capsulatumwere washed in PBS, kept at 37 °C for
12 h in RPMI medium without serum, and washed twice in PBS by
centrifugation. Yeasts were incubated with mβCD (40 mM) (Sigma)
in PBS for 30 min at 37 °C, supernatant was removed, and yeasts
were washed in PBS again to remove ergosterol extracted by mβCD.
Yeasts were then stirred with glass beads as above to disrupt cell
walls, and the suspension was incubated at a ﬁnal concentration of
1% Brij 98 for 30 min at 4 °C. DRMs were isolated by ultracentrifuga-
tion on sucrose gradient, as described above, and control cells were
suspended in PBS without mβCD [26].
2.4. SDS-PAGE and Western blotting
Twenty-ﬁve μL of each fraction obtained by sucrose gradient ultra-
centrifugation was analyzed by 8% SDS-PAGE. A 2.5 μL volume of frac-
tions 11 and 12 was used for better band visualization; this
adjustment was necessary to avoid saturation in SDS-PAGE. Protein
proﬁles were visualized by Coomassie Blue or Silver staining; alterna-
tively, proteins were transferred to polyvinylidene diﬂuoride (PVDF)
membranes. Membranes were then blocked with 10% non-fat dry
milk in TBST (200 mM Tris buffer, pH 8.0, containing 150 mM NaCl
and 0.1% Tween 20) for 1 h, and incubated with antibody anti-
Pma1p (Santa Cruz, CA, USA) or anti-α5-integrin (Cell Signaling, MA,
USA) diluted in 1% bovine serum albumin (BSA) in TBST (TBST-BSA).
Membranes were incubated overnight at 4 °C, then incubated 1 h at
room temperature with horseradish peroxidase (HRP)-conjugated
anti-goat or anti-mouse antibody (Santa Cruz). After each step, mem-
branes were washed 3× with TBST. Finally, samples were incubated
with chemiluminescence reagent (Pierce, IL, USA), and reactive pro-
teins were visualized by the photodocumentation system G-BOX HR-
16, analyzed and quantiﬁed by GeneTools software (Syngene) [27].
2.5. Binding of laminin to proteins obtained after density sucrose gradi-
ent ultracentrifugation
Proteins obtained after ultracentrifugation were transferred to
PVDF membranes as described above. Membranes were blocked
overnight with 10% non-fat dry milk in TBST, incubated for 1 h in
TBST-BSA containing 30 μg/mL laminin (Sigma), and washed 4× in
TBST. The PVDF membranes were then incubated for 2 h with anti-
laminin antibody (diluted 1:1000) (Sigma) in TBST-BSA, washed in
TBST, and incubated with HRP-conjugated anti-rabbit immunoglobu-
lin (Santa Cruz) (diluted 1:1000) [28]. Reactive proteins were visual-
ized and analyzed as described above.
2.6. Immunoprecipitation
Microdomain fractions obtained after sucrose gradient ultracentri-
fugation (Fr. 4 and 5, about 400 μg) were pre-cleared with Protein A-
Sepharose 4B (3 h at 4 °C, under agitation), and the supernatants
were incubated with laminin (30 μg, under agitation, overnight at
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with 6 μg of anti-laminin antibody (Sigma) in the presence of 500 μL
of TNE buffer containing 1% Brij 98 (under agitation, overnight at
4 °C). After overnight incubation the Sepharose Protein A containing
anti-lamin linked non-covalently was washed three times with TNE
buffer andmixed with microdomain fraction pre-incubated with lam-
inin (6 h, under agitation at 4 °C). After incubation the samples were
centrifuged, the pellet was washed two times with TNE, suspended in
100 μL of sample buffer, boiled for 3 min, centrifuged, and their su-
pernatant was applied on 12% SDS-PAGE. The gel was stained with
SilverSNAP Stain Kit II (Pierce) according to the manufacturer's in-
structions. Proper controls were carried out omitting laminin incuba-
tion with microdomain fraction, or omitting anti-laminin incubation
with Sepharose Protein A.2.7. Lipid analysis
GSLs were analyzed by HPTLC on Silica Gel 60 Plates (Merck,
Darmstadt, Germany) using chloroform/ methanol/CaCl2 0.02%
(60:40:9; v/v/v) (SolventA) asmobile phase. Glycolipidswere visualized
by staining with orcinol/H2SO4. Phospholipids were analyzed by HPTLC,
developed in chloroform/ methanol/methylamine 40% (60:35:10, v/v/v)
(Solvent B), and visualized as blue spots using Dittmer–Lester reagent
[29]. Ergosterol was analyzed by HPTLC using chloroform/ethyl
ether/acetic acid (97:2.5:0.5, v/v/v) (Solvent C) as mobile phase,
and visualized as gray spots using copper sulfate reagent (10%
CuSO4.5H2O in 3% H3PO4). GSLs, phospholipids, and ergosterol
were quantiﬁed by densitometric analysis (Scion Image Beta 4.02
and Image J 1.25) of HPTLC plates, in comparison to standard sample
(1 mg/mL), phospholipids and ergosterol from Matreya (PA, USA),
and GSLs puriﬁed from fungi [30–32].2.8. Gas chromatography coupled with mass spectrometric analysis
(GC–MS)
50 μL aliquots from pooled fractions (5–6 and 10–12) were
extracted by chloroform/methanol/water partition [33], and dried in
Pyrex tubes with Teﬂon-lined screw caps. Methanolysis was per-
formed by adding 1.0 mL of 1 M HCl in anhydrous methanol
(MeOH/HCl) and heating at 80 °C for 16 h. The cooled methanolysate
was partitioned 3× with an equal volume of hexane. Combined hex-
ane phases containing fatty acid methyl esters (FAMEs) were dried
under N2 stream at 37 °C, resuspended in 100 μL hexane, and ana-
lyzed by GC–MS [34]. Analysis was performed on a Varian CP-3800/
1200L using a CP-Sil 8 CB column, with splitless injection. Samples
were analyzed with temperature programming from 40 to 300 °C at
5 °C/min, then a 5 min plateau at 300 °C. Derivatives were identiﬁed
based on their retention times and mass spectra, in comparison to au-
thentic standards and published data [26].2.9. Preparation of methyl-β-cyclodextrin: sterol complexes
Complex formation between sterol (cholesterol or ergosterol)
(Sigma) and mβCD was performed essentially as described by Chris-
tian et al. and Zidovetzki and Levitan [35,36], with minor modiﬁca-
tions. A 5 mM water-soluble solution of mβCD–sterol complex was
prepared as follows. 118 μL of sterol (50 mg/mL) in choroform/meth-
anol 1:1 (v:v) was added to a glass tube, dried under nitrogen stream,
and dissolved in 3 mL distilled water. 171 mg mβCD was added, and
the mβCD/sterol solution was vortexed and sonicated for 3 min. The
saturated solution was placed in a rotating incubator at 37 °C over-
night, and soluble sterol was ﬁltered using 0.45 μm cellulose mem-
brane (Millipore, MA, USA). The ﬁltrate contained soluble mβCD–
sterol complex (40 mMol: 5 mMol).2.10. Preparation of alveolar macrophages
Alveolar macrophages were harvested by bronchoalveolar lavage
of BALB/c mice with 1.0 mL PBS at 37 °C. Lavage ﬂuid was carefully re-
moved following gentle massage of the chest. Macrophages were
washed 3× with cold PBS by centrifugation at 400×g, and the pellet
was suspended in RPMI 1640 supplemented with 10% fetal calf
serum, 10 mM HEPES, and penicillin (100 U/mL)/streptomycin
(100 μg/mL). ~5×105 macrophages were placed on sterile glass cov-
erslips on 24-well plates for 1 h at room temperature. Non-adherent
cells were removed by washing 3× with RPMI 1640, and the plates
kept at 37 °C in a CO2 incubator. Research ethical approval (CEP
0023/06) was granted by the Ethical Research Committee Board, Uni-
versidade Federal de São Paulo.
2.11. Infectivity of yeast forms of H. capsulatum after mβCD treatment
H. capsulatum yeast forms were pre-incubated with or without
mβCD (40 mM), and mβCD-treated yeasts were incubated or not
with 5 mM exogenous soluble ergosterol or cholesterol at 37 °C for
1 h, in order to replenish membrane sterol. All yeast preparations
were washed with PBS twice and cultured with alveolar macrophages
in 24-well plates (5 yeasts/macrophage; 2.5×106 yeasts/well) for 1 h
in RPMI 1640 without serum at room temperature. Non-adherent
yeasts were removed by washing the monolayer with medium. Mac-
rophages were ﬁxed with 4% formaldehyde for 10 min, and stained
with HEMA-3 solution. Phagocytic index was determined by multi-
plying the percentage of macrophages that had phagocytized at
least one yeast by the average number of yeasts per infected macro-
phage (300 macrophages were examined) [26]. Alternatively, non-
adherent yeasts were removed by washing the monolayer with medi-
um, the infected cells were harvested and lysed by ten strokes
through a 24-gauge needle. The lysates were centrifuged and yeasts
were suspended in 500 μL of PBS. Samples were diluted 65 times in
BHI medium, 50 μL of each solution was plated onto 6-well BHI-agar
plates, followed by incubation for 3 days at 37 °C, and colony count-
ing. All experiments were repeated three times in triplicates.
3. Results
3.1. Lipid distribution in detergent-resistant membrane microdomains
(DRMs) of H. capsulatum isolated at 4 °C
Membranes of H. capsulatum yeast forms treated with 1% Brij 98 at
4 °C were fractionated on a sucrose gradient by ultracentrifugation,
and 1.0-mL fractions were collected from top to bottom. (Glyco)
lipid proﬁles of twelve fractions were analyzed by HPTLC. GSLs were
found mainly in Fr. 5 and 6 (low-density fractions — raft fractions),
and Fr. 9–12 (high-density fractions and detergent) (Fig. 1A). Signiﬁ-
cant amounts of ergosterol and phospholipids were detected in Fr.
4–7 (low-density membranes) (Fig. 1B, C). Quantiﬁcation of (glyco)
lipid components by densitometry of HPTLC plates showed that Fr.
4–7 contain ~25% of total GSLs, 42% of total ergosterol, and 36% of
total phospholipids. These ﬁndings indicate that low-density DRMs
of H. capsulatum are found in Fr. 5 and 6, similar to those observed
in mammalian cells [25,37]. Other non-ionic detergents, Tween 20
and Triton X-100, were less efﬁcient than Brij 98 for isolation and re-
covery of DRMs (data not shown).
In order to analyze the composition of fatty acid of GSLs and phos-
pholipids present in detergent-insoluble and -soluble membranes, Fr.
5 and 6 and Fr. 10 to 12 were pooled. Lipids (50 μL of pooled frac-
tions) were derivatized as fatty acid methyl esters (FAMEs), and ana-
lyzed by GC–MS. As shown in Fig. 2, about 80% of fatty acids present
in Fr. 5–6, consisted of saturated C16 and C18, and 20% was unsaturat-
ed C18:1 and C18:2. In contrast, in Fr. 10–12, only 42% of fatty acids
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Fig. 1. Lipid proﬁle of fractions obtained by sucrose density gradient ultracentrifugation
of H. capsulatum.H. capsulatum yeast forms were lysed with 1% Brij 98 at 4 °C, and sub-
jected to sucrose density gradient ultracentrifugation to isolate membrane microdo-
mains. Twelve fractions were collected, from top to bottom of the tube. Lipid
components were analyzed by HPTLC developed in the following solvents. Panel A: sol-
vent A; GSLs stained with orcinol/H2SO4. Panel B: solvent B; ergosterol stained with
Cu2SO4. Panel C: solvent C; phospholipids stained with Dittmer–Lester reagent. T:
total fraction; GSL: GSL standard mixture containing monohexosylceramide (MHC)
and glycoinositol phosphorylceramide (GIPC). Erg: ergosterol standard. Pho: phospho-
lipid standard mixture containing phosphatidylethanolamine (PE), phosphatidylcho-
line (PC), phosphatidylserine (PS), and phosphatidylinositol (PI). n.r. = nonraft
fractions. Or., origin. Results shown are representative of three or more experiments.
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Fig. 3. Lipid proﬁle of ultracentrifugation fractions obtained at 37 °C.Panels A, B, C: H.
capsulatum yeast forms were lysed with glass beads and incubated with Brij 98 for
30 min at 37 °C. The lysate was subjected to sucrose density gradient ultracentrifuga-
tion, and 12 fractions were obtained. Panels D, E: mammalian cells (NS-1) were incu-
bated with Brij 98 for 30 min at 4 °C (D) or 37 °C (E). The lysate was subjected to
ultracentrifugation, and 7 fractions were obtained. Lipid components were analyzed
by HPTLC, developed in the following solvents. Panels A, D, E: solvent B; ergosterol
and cholesterol stained with Cu2SO4. Panel B: solvent A; GSLs stained with orcinol/
H2SO4. Panel C: solvent C; phospholipids stained with Dittmer–Lester reagent. n.r. =
nonraft fractions. Abbreviations are the same as in Fig. 1. Results shown are represen-
tative of three or more experiments.
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C18:2.
3.2. DRMs isolated at low vs. high temperature
To compare the stability of membrane microdomains of H. capsu-
latum yeast forms, vs. those of mammalian cells, yeast forms were
disrupted with glass beads at 4 °C, and incubated with 1% Brij 98 in
TNE buffer for 30 min at 4 °C and 37 °C. Stability of membrane micro-
domains at 37 °C was determined after sucrose gradient ultracentri-
fugation and HPTLC analysis. Distributions of ergosterol, GSLs, and
phospholipids in the fractions are shown in Fig. 3A, B, C. DRMs were
observed in Fr. 4 to 7 at both 4 °C and 37 °C. Ergosterol, GSL, and50
Pe
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) 40
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Fig. 2. GC/MS quantiﬁcation of fatty acids from H. capsulatum Fr. 5–6 and Fr.
10–12.50 μL aliquots from pooled Fr. 5–6 (black bars) and Fr. 10–12 (gray bars) as
shown in Fig. 1 were analyzed by GC/MS. Fatty acid chains were identiﬁed on the
basis of retention time and fragmentation pattern.C16:0: hexadecanoic acid (palmitic
acid). C18:0: octadecanoic acid (estearic acid). C18:1: cis-9-octadecenoic acid (oleic
acid). C18:2: 9,12-octadecadienoic acid (linoleic acid). Results shown are representa-
tive of three or more experiments. *Signiﬁcantly different from Fr.5–6 at pb0.0001.phospholipid proﬁles were similar for DRM fractions isolated at 4 °C
(Fig. 1) or 37 °C (Fig. 3). These results suggest that membrane micro-
domains of H. capsulatum are resistant to 1% Brij 98 treatment at
37 °C. In contrast, for mammalian cells, DRMs are isolated only at
4 °C (Fig. 3D); at 37 °C, microdomains are completely solubilized,
and cholesterol (Fig. 3E) and GSLs (not shown) are completely dis-
placed from raft- to non raft-fractions.
3.3. Protein distribution in DRMs
Protein distribution in the sucrose gradient fractions was analyzed
by SDS-PAGE and visualized by Coomassie Blue, Silver staining or
Western blotting. The relative protein distribution was calculated by
densitometric analysis. As shown in Fig. 4A (‘Control’), by SDS-
PAGE, two protein populations were enriched in microdomain Fr. 5
and 6 at 30 kDa (“a”) and 50–55 kDa (“b”). Anti-Pma1p antibody
(Fig. 4B, left panel), and anti-α5-integrin antibody (Fig. 4D, left)
stained preferentially components of ~100 kDa and ~50–55 kDA, re-
spectively. By densitometry it was found that about 90% of the
~100 kDa component and 52% of the ~50–55 kDa component were
Control mβCD
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Fig. 4.Microdomain proteins of H. capsulatum yeast forms with or without mβCD treatment. H. capsulatum yeast forms were treated or not with mβCD. 25 μL of Fr. 1–10 and 2.5 μL
of Fr. 11–12 were subjected to 8% SDS-PAGE, transferred to PVDF membrane, and analyzed as follow: Panel A: Coomassie Blue staining. Panel B: Western blotting using anti-Pma1p
antibody. Panel C: Western blotting assayed by incubating PVDF membrane with laminin (30 μg/ml) followed by anti-laminin antibody. Panel D: Western blotting using anti-α5-
integrin antibody. Panel E: SDS-PAGE Silver staining of laminin immunoprecipitation of microdomain fractions (Fr. 5 and 6) isolated from yeast forms of H. capsulatum control (Lane
1) or mβCD treated (Lane 2). Laminin-immunoprecipitation controls were carried out omitting microdomain fractions (Lane 3) or omitting laminin incubation with microdomain
fractions (Fr. 5 and 6) isolated from yeast forms of H. capsulatum (Lane 4).
462 L. Tagliari et al. / Biochimica et Biophysica Acta 1818 (2012) 458–466present in microdomain Fr. 4–7. Laminin-binding assay and densito-
metric analysis showed that 77% of the 30 kDa laminin-binding pro-
tein was found in Fr. 4–7 (Fig. 4C, left). To conﬁrm the laminin
binding speciﬁcity to native 30 kDA protein, an immunoprecipitation
assay was carried out using laminin, anti-laminin antibody and
Sepharose Protein A. Under these conditions only the 30 kDa protein
was immunoprecipitated, as shown in Fig. 4E, lane 1.Erg
GIPCs
A B
1 2 3 4 1 2 3 4
Or.Or.
Fig. 5. Extraction of ergosterol from H. capsulatum yeast forms with 40 mM mβCD.H.
capsulatum yeast forms were incubated with 40 mM mβCD for 1 h at 37 °C, centri-
fuged, and supernatants were collected. To assess the efﬁciency of lipid extraction by
mβCD, supernatant was extracted with 1-butanol, and the pellet was washed with
PBS and extracted with isopropanol/hexane/water (55:20:25, v/v/v). Panel A: HPTLC
developed in solvent B; ergosterol stained with Cu2SO4. Panel B: HPTLC developed in
solvent A; GSLs stained with orcinol/ H2SO4. Lane 1: lipid fraction extracted from
yeast cells not treated with mβCD. Lane 2: lipid fraction from cells treated with
40 mM mβCD. Lane 3: lipid fraction from culture supernatant of cells not treated
with mβCD. Lane 4: lipid fraction from culture supernatant of cells treated with
40 mMmβCD. Results shown are representative of three or more experiments.3.4. Effect of mβCD on DRMs
To investigate the importance of ergosterol in DRMs of H. capsula-
tum, yeast forms were incubated with mβCD at 40 mM, and subse-
quent viability was tested by: (i) staining with live/dead yeast
(Invitrogen, CA, USA); (ii) determination of colony-forming units
(CFU) [38]. Untreated vs. treated mβCD-yeast were found to be
equally viable by the two methods.
Lipids were extracted from mβCD-treated cells and from culture
supernatants and both these extracts were analyzed by HPTLC.Table 1
Distribution of lipids and proteins of H. capsulatum yeast forms with or without mβCD
treatment, after sucrose density gradient ultracentrifugation. Fractions were pooled
according to HPTLC and SDS-PAGE results.
Control mβCD
Fractions 4–7
(μg)
10–12
(μg)
4–7
(μg)
10–12
(μg)
Erga 49.1±5.9 38.4±6.9 7.3±4.0 15.0±5.7
GIPCa 13.9±3.5 24.9±5.1 14.6±3.1 32.1±6.6
MHCa 12.2±2.7 15.9±5.1 12.4±2.4 19.8±6.9
Phoa 17.8±3.5 15.3±3.9 10.2±2.9 23.1±6.6
Proteina 878±29.2 14,421±45 464±25 13,161±51
Erg = ergosterol; GIPC = glycoinositol phosphorylceramide; MHC = monohe
xosylceramide; Pho = phospholipid. Lipids were quantiﬁed by densitometric parameters
using appropriate standard; protein was quantiﬁed by Micro BCA Protein Assay Kit
(Pierce). Fr. 1–3 and Fr. 8–9 are omitted because of low concentration, or absence.
a Components are expressed as μg per pooled fraction.
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remaining 91% of membrane GIPCs (Fig. 5B).
DRMs were isolated from cells incubated with 40 mM mβCD by
sucrose density gradient ultracentrifugation, as described in Section
2.3, and resulting fractions were analyzed by HPTLC. GSL proﬁles of
detergent-insoluble (Fr. 4–7) vs. -soluble fractions (Fr. 10–12) did
not differ signiﬁcantly between mβCD-treated vs. non-treated cells
(Table 1). These ﬁndings indicate that mβCD selectively extracts er-
gosterol from yeast membrane, and ergosterol removal does not af-
fect GSL composition in DRMs.
On the other hand, SDS-PAGE analysis showed that removal of
ergosterol did result in a partial change of protein proﬁle. mβCD
treatment of yeast cells caused a 45% reduction of protein in Fr. 5
and 6 (Fig. 4A, right), with displacement of Pma1p and 30 kDaControl
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Fig. 6. H. capsulatum infectivity assay using alveolar macrophages. Panel A: Alveolar macro
and incubated with H. capsulatum yeast forms pre-treated with or without 40 mM mβCD, fo
rol), in 5:1 proportion of yeasts/macrophage. Coverslips were then washed, ﬁxed with 4% fo
macrophages are indicated by arrows. Panel B: Phagocytic index was determined by multip
average number of yeasts per infected macrophage; 300 cells were examined. Experiments
*Signiﬁcantly different from control at pb0.0001; **signiﬁcantly different from control at pb
plated on a petri dish containing BHI-agar medium, and incubated for 3 days at 37 °C. Colony
**signiﬁcantly different from control at pb0.005.laminin-binding protein to soluble fractions (Fr 9–12), as shown
by Western blotting (Fig. 4B and C, right). Densitometric analysis
revealed that after mβCD treatment only 10% of Pma1p and 16% of
30 kDa laminin-binding protein remained in microdomain Fr. 4–7,
comparing to 90% of Pma1p and 77% of the 30 kDa laminin-
binding protein found in the Fr. 4–7 of non-treated yeasts. As
expected the proportion of Pma1p and 30 kDa protein in soluble
Fr. 10–12 increased from 2.7% and 7% to 63% and 69%, respectively.
In agreement with this data, no 30 kDa protein was immunoprecipi-
tated when laminin and anti-laminin-Sepharose-Protein A were in-
cubated with mβCD-yeast microdomain fractions (Fig. 4E, lane 2).
Reactivity of anti-α5-integrin antibody with the 50 kDa protein of
yeast forms treated or not with mβCD was detected mainly in
microdomain Fr. 4–7 (50% and 52%, respectively), as shown inmβCD
mβCD + Cho
mβCD mβCD mβCDcontrol 0
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200
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CF
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phages of BALB/c mice were collected by bronchoalveolar lavage, placed on coverslips,
llowed by 1 h incubation with exogenous ergosterol or cholesterol (5 mMmβCD: ste-
rmaldehyde in PBS, stained with HEMA-3, and analyzed by optical microscopy. Infected
lying the percentage of macrophages that had phagocytosed at least one yeast by the
were repeated 3×, in triplicate. Results shown are representative of these experiments.
0.005. Panel C: Yeast forms of H. capsulatum recovered from infected macrophages were
forming units (CFUs) were counted. *Signiﬁcantly different from control at pb0.0001;
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ergosterol-independent microdomain.
3.5. Importance of microdomain integrity in the infectivity of alveolar
macrophages
To determine the role of ergosterol-dependent membrane micro-
domains in infection of alveolar macrophages, H. capsulatum yeast
forms were treated with 40 mM mβCD, washed with PBS, and then
incubated with macrophages isolated from lungs of BALB/c mice.
Treatment of the yeast forms with mβCD reduced macrophage infec-
tion by ~45% (Fig. 6A and B, control and mβCD).
Next, the ability of exogenous soluble sterols (cholesterol, ergosterol)
incorporated intomembranemicrodomains to restoremacrophage infec-
tivity was evaluated. To ascertain whether exogenous sterols were incor-
porated into plasma membrane and restored membrane microdomains,
mβCD-treated yeasts were incubated with exogenous sterols, lysed, and
microdomains were isolated by ultracentrifugation. HPTLC analysis con-
ﬁrmed that exogenous ergosterol (Fig. 7B) and cholesterol (Fig. 7C)
were incorporated into DRM-containing Fr. 4–7. In the same set of exper-
iment itwas analyzedwhether sterol reincorporationwas able to reinsert
the 30 kDa laminin-binding protein in membrane microdomain and its
relative distribution in microdomain and non-microdomain fractions
was determined by densitometric analysis. As shown in Fig. 7D, in controlErg
mβCD
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Fig. 7. Sterol and 30 kDa protein proﬁles ofH. capsulatum treated with mβCD, and effect
of exogenously-added ergosterol and cholesterol.H. capsulatum yeast forms were trea-
ted with mβCD, then incubated with or without 5 mM exogenous water-soluble ergos-
terol or cholesterol, washed extensively with PBS, and lysed with glass beads. The lysate
was incubatedwith Brij 98 for 30 min, subjected to sucrose density gradient ultracentri-
fugation, and 12 fractions were collected from top to bottom of the tube, and analyzed
as follows: sterols were analyzed by HPTLC developed in solvent B and stained with
Cu2SO4. Panel A: Ergosterol proﬁle of mβCD treated yeasts. Panel B: Ergosterol proﬁle
of mβCD treated yeasts with exogenous ergosterol addition. Panel C: Cholesterol proﬁle
of mβCD treated yeasts with exogenous cholesterol addition. Results shown are repre-
sentative of three or more experiments. Also, proteins were subjected to 8% SDS-PAGE,
transferred to PVDF membrane, and Western blot assayed by incubating PVDF mem-
brane with laminin (30 μg/ml) followed by anti-laminin antibody. Panel D: laminin-
binding protein proﬁle of control yeasts. Panel E, laminin-binding protein proﬁle of
mβCD treated yeasts. Panel F: laminin-binding protein proﬁle of mβCD treated yeasts
with exogenous ergosterol addition. Panel G: laminin-binding protein proﬁle of mβCD
treated yeasts with exogenous cholesterol addition. n.r. = nonraft fractions.experiments 88% of the 30 kDa laminin-binding protein is found in the
microdomain Fr. 4–7, upon treatment with mβCD only 13% of the
30 kDa protein remains in the Fr. 4–7, and about 52% of the 30 kDa pro-
tein is displaced to non-raft Fr. 10–12 (Fig. 7E). As observed in Fig. 7F,
ergosterol-reinserted yeasts show that 76% of the 30 kDa laminin-
binding protein is reinserted in microdomain Fr. 4–7. On the other
hand, for mβCD-treated yeasts incubated with exogenous cholesterol,
no reinsertion of the 30 kDa laminin-binding was observed in microdo-
main Fr. 4–7,which present about 10% of the 30 kDa laminin binding pro-
tein, whereas about 61% of the 30 kDa laminin-binding protein remained
in Fr. 10–12 (Fig. 7G).
Finally, yeast forms treated with mβCD were incubated or not
with exogenous ergosterol or cholesterol, and macrophage infectivity
was analyzed. Infectivity of mβCD-treated cells was restored by incu-
bation of mβCD-treated cells with ergosterol (Fig. 6A, B, ‘mβCD+
Erg’), but not with cholesterol (‘mβCD+Cho’), indicating that only
ergosterol has the structural requirement to restore fungal DRM's
organization needed for H. capsulatum infectivity. The macrophage
infection rate by H. capsulatumwas also determined by colony forma-
tion units (Fig. 6C) for each experimental condition, ‘mβCD’ and
‘mβCD–Cho’ treatment reduced colony formation to approximately
37% and 42% of that observed in controls, while ‘mβCD–Erg’ restores
H. capsulatum infectivity, corroborating the infectivity index results.
4. Discussion
Isolation of membrane microdomains of fungal species such as Sac-
charomyces cerevisiae[24], Candida albicans[39,40], and Cryptococcus
neoformans[41] has been reported during the past decade. However,
components and functions of membrane microdomains of pathogenic
fungi remain poorly understood [11,42,43]. In the present study, we
characterized membrane microdomains isolated from yeast forms of
H. capsulatum, and their possible role in macrophage infectivity.
4.1. Components of membrane microdomains of H. capsulatum
Analysis of lipid content showed that ergosterol is the main lipid
in the microdomain fraction (42%), followed by phospholipids (36%)
and GSLs (25%).
Western blotting showed that Pma1p, the major plasma mem-
brane proton ATPase, is present mainly in DRMs [44], particularly in
ergosterol-dependent microdomains. Binding experiments using
PVDF membrane containing sucrose gradient fractions, also showed
binding of laminin to a ~30 kDa protein localized in DRMs, Fr. 5–6,
which was immunoprecipitated by addition of laminin and anti-
laminin-Sepharose A. It is feasible that this 30 kDa laminin-binding
protein may belong to a family of fungal adhesins, since a similar
laminin-binding protein was also described in Paracoccidioides brasi-
liensis[28]. Further studies along this line may reveal relevant new
data regarding a possible fungal adhesion protein family related to
fungal infectivity. The identiﬁcation of a possible H. capsulatum adhe-
sin located in DRM has important implications for yeast interactions
with host cells and other substrates, since adhesion is the ﬁrst step
in the infection process.
4.2. Isolation of membrane microdomains of H. capsulatum at 37 °C
H. capsulatum microdomains were isolated either at 4 °C or 37 °C
and presented similar composition of ergosterol and glycosphingoli-
pids. However, microdomains isolated at 37 °C presented reduction
of phospholipids, only 23% of phospholipids remain in DRM fractions,
vs 36% in microdomains isolated at 4 °C.
In mammalian cells isolation of membrane microdomains is possi-
ble using non-ionic detergent at 4 °C [37,45–47], but it is not feasible
at 37 °C [48]. One possible explanation for the maintenance of fungal
cell microdomains at 37 °C is the ﬁnding of Czub and Baginski [49]
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cholesterol-containing membranes, and thus they are more resistant
to detergent. Our results are also consistent with those of Xu et al.
[50], who showed that ergosterol is able to form areas that are more
stable at high temperatures (e.g., 37 °C) than cholesterol. This could
be related to structural differences between ergosterol and cholester-
ol, i.e., ergosterol has an additional double bond between carbons 7
and 8 of ring B, between carbons 22 and 23, and a methyl group at
C-24 aliphatic chain, which may promote stability through a more
orderly-packed lipid raft.
4.3. Ergosterol-dependent and -independent membrane microdomains
mβCD treatment resulted in extraction of 85% of ergosterol pre-
sent in H. capsulatum membranes, but did not signiﬁcantly alter pro-
ﬁles of GSLs or phospholipids. Along this line, Hakomori [47] and
Westerlund and Slotte [51] reported the ability of GSLs to form mem-
brane microdomains independently of sterols, possibly due to strong
compaction of hydrophobic regions of GSL molecules, and stabiliza-
tion by hydrogen bonds at the ceramide portion.
mβCD treatment did alter protein proﬁle in DRMs, by shifting pro-
teins, such as the 30 kDa laminin-binding protein and Pma1p, to sol-
uble fractions.
Results from mβCD experiments suggest that both ergosterol-
dependent and ergosterol-independent microdomains are present
in H. capsulatum plasma membranes, since it was detected presence
of microdomains enriched in GSLs and α5 integrin-like protein even
after ergosterol removal by mβCD. Integrin-like molecules have
been also described in C. albicans surface [52,53], such as the 37 kDa
alcohol dehydrogenase, a protein recognized by antibody directed to
α5β1 integrin described by Klotz et al. [54].
An attractive hypothesis for an integrated functionality of fungal
membrane, would be different populations of DRMs such as ergosterol-
dependent and ergosterol-independent present in yeast forms of H. cap-
sulatum, acting in a concerted way allowing key molecules to exert their
biological roles in a more efﬁcient way.
4.4. Importance of membrane microdomains in infectivity of alveolar
macrophages
H. capsulatum infectivity to BALB/c alveolar macrophages was re-
duced signiﬁcantly (45%) after mβCD treatment, suggesting that the
infectivity requires integrity of ergosterol-dependent fungal mem-
brane microdomains. Similarly, Cossart et al. [55] demonstrated the
importance of host membrane microdomain integrity by showing
that infection of cholesterol-depleted Vero cells by the bacterium Lis-
teria monocytogenes was reduced by 50%, and that infectivity was re-
stored by addition of cholesterol. In this context we described earlier
that treatment of Leishmania (Viannia) braziliensis with mβCD de-
creased macrophage infectivity by 52% [26].
In the present study, we showed that exogenous ergosterol can be
re-inserted into membranes of mβCD-treated yeast cells, and restore
their ability to infect alveolar macrophages. Addition of exogenous cho-
lesterol did not restore infectivity. Thus, ergosterol, but not cholesterol,
is essential for themaintenance of key structural and functional aspects
of membrane microdomains necessary for the H. capsulatum–host in-
teraction. A possible explanation may be due to the fact that only in
microdomain fractions containing ergosterol was observed the pres-
ence of a 30 kDa laminin-binding protein, similar to that described in
P. brasiliensis, as an adhesin able to bind to laminin [28], possibly re-
sponsible for H. capsulatum–macrophage interaction.
5. Conclusions
Detergent-resistant membrane microdomains (DRMs), obtained
after fractionation of H. capsulatum yeast forms were isolated bysucrose density gradient ultracentrifugation at 4 °C. These DRMs are
enriched in ergosterol, GSLs, and speciﬁc proteins, and remain stable
at 37 °C.
Protein analysis following treatment of DRMs with mβCD (a sterol
chelator, which extracts ergosterol from membranes) showed dis-
placement of Pma1p, and the laminin-binding 30 kDa protein from
DRM fractions (Fr. 4–7) to detergent-soluble fractions (Fr. 10–12).
Conversely, a 50 kDa integrin-like protein was not displaced from
DRMs to soluble fractions after mβCD treatment, suggesting the exis-
tence of microdomains whose integrity does not depend on ergoster-
ol. Removal of ergosterol of H. capsulatum yeast forms with mβCD
reduced the fungus ability to infect alveolar macrophage by 45%.
These ﬁndings suggest the existence in H. capsulatum yeast forms of
ergosterol-dependent DRMs where Pma1p and the 30 kDa laminin-
binding protein are inserted, and ergosterol-independent DRMs,
where 50 kDa integrin-like protein is inserted. It is noteworthy the
observation that reinsertion of ergosterol, but not cholesterol, was
able to fully restore the H. capsulatum ability to infect alveolar
macrophages.Acknowledgements
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